Amgen's earnings call highlighted strong performance despite the challenging market conditions.  Management expressed confidence in their ability to manage costs, maintain research and development, and achieve growth in 2008.  Positive data from the denosumab trials and the new guidance range indicate a likely positive short-term impact on stock price, fueled by strong pipeline growth and market share retention.
[2]
